Compare DRVN & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRVN | SYRE |
|---|---|---|
| Founded | 1972 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.6B |
| IPO Year | 2020 | 2015 |
| Metric | DRVN | SYRE |
|---|---|---|
| Price | $10.34 | $39.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $19.57 | ★ $55.57 |
| AVG Volume (30 Days) | ★ 2.3M | 693.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.82 | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $2,339,588,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.10 | N/A |
| P/E Ratio | $15.25 | ★ N/A |
| Revenue Growth | ★ 1.54 | N/A |
| 52 Week Low | $9.80 | $10.91 |
| 52 Week High | $19.74 | $45.76 |
| Indicator | DRVN | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 21.20 | 54.58 |
| Support Level | $9.80 | $38.36 |
| Resistance Level | $15.91 | $45.76 |
| Average True Range (ATR) | 0.59 | 1.93 |
| MACD | -0.19 | -0.43 |
| Stochastic Oscillator | 7.29 | 28.37 |
Driven Brands Holdings Inc is an automotive services company in North America. Its platform provides high-quality services to an extensive range of retail and commercial customers. The company provides an extensive range of core consumer and commercial automotive needs, including paint, collision, glass, and repair services, as well as a variety of high-frequency services, such as oil changes and car washes. The company segments include: Maintenance, Car Wash, Paint, Collision & Glass, and Platform Services. It derives maximum revenue from Maintenance Segment. Geographically, the company operates into United States, Canada and Rest of the World.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.